Midas Management Corp Maintains Stake in Amgen Inc. (AMGN)
Midas Management Corp maintained its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,500 shares of the medical research company’s stock at the end of the 2nd quarter. Amgen accounts for about 1.2% of Midas Management Corp’s holdings, making the stock its 29th biggest position. Midas Management Corp’s holdings in Amgen were worth $2,325,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of AMGN. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Amgen during the 1st quarter worth approximately $110,402,000. Swiss National Bank increased its stake in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after purchasing an additional 551,600 shares during the last quarter. Bank of Nova Scotia increased its stake in shares of Amgen by 414.4% during the 1st quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after purchasing an additional 484,868 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Amgen by 37.4% during the 1st quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after purchasing an additional 392,538 shares during the last quarter. Finally, Morningstar Investment Services LLC increased its stake in shares of Amgen by 283.8% during the 1st quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after purchasing an additional 367,894 shares during the last quarter. Institutional investors own 78.10% of the company’s stock.
Shares of Amgen Inc. (AMGN) opened at 186.85 on Friday. The company has a market capitalization of $136.34 billion, a P/E ratio of 17.02 and a beta of 1.36. The stock’s 50 day moving average is $180.82 and its 200-day moving average is $170.11. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. Amgen’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.46%. Amgen’s dividend payout ratio is 41.93%.
AMGN has been the subject of several research analyst reports. Cann restated a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 price target on shares of Amgen in a research note on Thursday, September 7th. Deutsche Bank AG initiated coverage on shares of Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 price target for the company. William Blair restated a “market perform” rating on shares of Amgen in a research note on Monday, June 26th. Finally, Mizuho restated a “buy” rating and set a $198.00 price target (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average target price of $189.35.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.